Tri-Niacin 250 mg Sustained Release Niacin by Douglas Laboratories — Ingredients, Evidence & Safety

Product Label

Label for Tri-Niacin 250 mg Sustained Release Niacin

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacin: 250mg is 7.1× the Tolerable Upper Intake Level (35mg)

This product received a low safety score because the amount of niacin in a single dose is over seven times higher than the recommended maximum daily limit.

Label Data

1 Capsule(s) Serving Size

250 Servings

Vitamin Product Type

100% Evidence Coverage

Supplement Facts — Evidence Check

Niacin

250 mg (1250% DV)

⚠️ Exceeds Tolerable Upper Intake Level by 7.1× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)

RDA 14mg This product: 250mg UL 35mg

Other Ingredients

Cellulose Gelatin

Label Claims — Verification

❓ All Other

All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years) Dairy Free

Product Information

📋 Directions for Use

Suggested Usage: As a dietary supplement, adults take 1 or more capsules daily or as directed by your healthcare professional.

⚠️ Warnings & Precautions

KEEP OUT OF REACH OF CHILDREN.

Tamper resistant package, do not use if outer seal is missing.

🧪 Formulation Notes

This product contains NO yeast, wheat gluten, soy protein, milk/dairy, corn, sodium, starch artificial coloring, preservatives or flavoring.

Additional Information

These capsules filled with beadlets are designed to release continuously over 4-6 hours.

For optimal storage conditions, store in a cool, dry place. (59(0)-77(0)F/15(0)-25(0)C) (35-65% relative humidity)

Formula #7927

Product Details

UPC / SKU 3 10539 02933 6

DSLD Entry Date 2012-06-25

Product Type Vitamin

Form Capsule

Brand Douglas Laboratories

DSLD ID 9216

Data Updated 2026-04-11

Research Evidence

241 Research Sources

55 Avg Quality Score

113 Meta Analysis

75 Systematic Review

32 Rct

11 Clinical Trial

3 Other

3 Regulatory Source

1 Cochrane Review

1 Narrative Review

1 Openfda Safety

A Niacin for primary and secondary prevention of cardiovascular events

Meta Analysis The Cochrane database of systematic reviews 2017

PubMed DOI Cochrane

A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases

Meta Analysis BMJ (Clinical research ed.) 2013

PubMed DOI

A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients

Meta Analysis BMJ (Clinical research ed.) 2014

PubMed DOI

A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk

Meta Analysis Nature medicine 2024

PubMed DOI

A Meta-analysis and imputation refines the association of 15q25 with smoking quantity

Meta Analysis Nature genetics 2010

PubMed DOI

A Genome-wide meta-analyses identify multiple loci associated with smoking behavior

Meta Analysis Nature genetics 2010

PubMed DOI

A Antidepressants for smoking cessation

Meta Analysis The Cochrane database of systematic reviews 2014

PubMed DOI

A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne

Meta Analysis The Cochrane database of systematic reviews 2020

PubMed DOI Cochrane

B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis

Meta Analysis JAMA network open 2019

PubMed DOI

B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis

Meta Analysis JAMA 2016

PubMed DOI

View all evidence for Niacin →